The anthelmintic drug fenbendazole (methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl) carbamate, commonly known as ‘fenben’) is an established broad-spectrum benzimidazole carboxamide anthelmintic that has been in veterinary use for several decades. It is effective against many gastrointestinal parasites, including pinworms, giardiasis, hookworms and whipworms as well as the cestodes Taenia solium and Taenia stenocephala, and trematodes Heterobilharzia americana and Paragonimus kellicotti1.
In a recent study, fenbendazole was found to have moderate microtubule depolymerizing activity in human cancer cells with the KRAS mutation. It was also found to suppress RAS-related signaling pathways in these cells, and to inhibit tumor growth in mice bearing a KRAS-mutant lung cancer cell line. The authors noted that fenbendazole also showed B cell activation inhibitory and antiproliferative effects in vitro.
Similarly, in a mouse model of allergic airway disease induced by ovalbumin exposure, fenbendazole was shown to reduce the severity of bronchoalveolar lavage fluid eosinophilia and bronchitis. The authors attributed the results to the fact that fenbendazole reduced the number of goblet cells in the lungs of treated mice, and that these effects were mediated by a reduction in the production of proinflammatory cytokines.
The fenben lab fenbendazole has long been used as an antiparasitic medication and is approved for a wide range of animal species. It is a member of the broad-spectrum benzimidazole family, which has been safely used as anthelmintics for about six decades. Repurposing veterinary drugs that show promising results in laboratory experiments can save significant time and money in the development of new medicines. fenben lab fenbendazol